导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 26.16% | 202/4772 |
| 近一周 | 0.95% | 782/5464 |
| 近一月 | -9.24% | 4180/5418 |
| 近一季 | -15.93% | 4252/5236 |
| 近半年 | 24.65% | 173/4930 |
| 近一年 | 27.79% | 249/4399 |
| 近两年 | 164.26% | 168/2954 |
| 近三年 | 127.72% | 60/2253 |
| 成立以来 | 66.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.40% 4126/4961 |
86.81% 142/5312 |
- - |
- - |
| 2025 | 45.95% 600/4813 |
1.95% 1506/3635 |
-0.45% 2928/4076 |
53.68% 242/4524 |
-6.43% 3710/4813 |
| 2024 | 23.32% 340/3463 |
-5.76% 1947/2808 |
2.58% 338/3014 |
14.19% 2028/3129 |
11.71% 204/3463 |
| 2023 | 5.35% 190/2656 |
19.39% 146/2280 |
-3.52% 814/2385 |
-8.46% 1702/2515 |
-0.09% 178/2655 |
| 2022 | -37.29% 1752/2207 |
-24.91% 1779/1919 |
0.65% 1534/2016 |
-19.02% 1746/2113 |
2.45% 935/2208 |
| 2021 | 10.35% 433/1822 |
-8.89% 1097/1255 |
21.28% 137/1330 |
-8.88% 1160/1466 |
9.61% 116/1822 |
| 2020 | - - |
- - |
29.80% 69/1067 |
2.73% 999/1164 |
6.74% 746/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 天弘中证电子ETF VS. 长安沪深300非周期A(740101) |